Interleukin-6 blockade modulates monocyte recruitment to protect against diastolic dysfunction associated with inflammatory arthritis.

BACKGROUND: There is an unmet clinical need to manage heart failure with preserved ejection fraction in people with rheumatoid arthritis (RA). One hurdle is the absence of preclinical models to study pathology and pharmacology in settings of inflamma…

Preview only. Read the full abstract at the source